CClinicalTrials.gg
CompletedNCT05407337SINDIANEUpdated Aug 9, 2024

The Effect of Narrative Exposure Therapy Intervention on Post-traumatic Stress Dissorder and Personal Recovery in Refugees and Asylum Seekers of Sindiane Programme

An interventional study of Psychotherapy using Narrative Exposure Therapy (NET) in Post-traumatic Stress Disorder (PTSD), sponsored by Assistance Publique Hopitaux De Marseille. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Displaced people, like refugees or asylum seekers, have high rate of potentially traumatic events. PTSD is one of the most common psychiatric trouble in this population. It requires specialized support and psychosocial program. Narrative Exposure Therapy (NET), a german psychotherapy, was developed in the 2000 to specifically treat psycho-trauma in this population. It is brief, effective on complex trauma and can be delivered by trained non-caregivers. All published randomized studies have conclued that NET is effetive, but there are still insifficient numbers to make recomendations. To our knowledge, NET has never been tested in France. In Marseille, SINDIANE is a community support and program for refugees and asylum seekers. Many workshops led by peer workers are offered to increase empowerment of beneficiaries and hel them to recover. The development of a NET workshop would make it possible to combine community support and specific and validated psychotherapy. Through this study, the investigators hypothesize that tratment of PTSD with NET in the community-based SINDIANE program decrease symptoms of PTSD.

Read the detailed description

Methods and design Forty-six participants with a diagnosis of PTSD disorder within the SINDIANE program will be recruited. A prospective single-blind randomized clinical trial will be conducted comparing two groups, one participant in the classic SINDIANE program and one being treated in addition by NET workshp. The evaluations will be done at the baseline, after the intervention and at three and six months follow-up. IN addition, the qualitative and participatory research method called photovoice will be used to better understand the experiences of participants who recieve NETtroughout their recovery.

The primary objective is the assessment of the symptom intensity score (PCL-5) of posttraumatic stress disorder (PTSD).

Secondary objectives are represented by:

  • The assessment of the stability over time of the PTSD symptom intensity score at three months and six months (PCL-5).
  • Assessment of the intensity of global psychiatric comorbidities (RHS-15)
  • Evaluation of life indicators: ability to act, quality of life (GSE self-efficacy questionnaire).
02

Conditions studied

  • Post-traumatic Stress Disorder (PTSD)
03

In context

Stress Disorders, Traumatic

1,147 studies on the registry are indexed under Stress Disorders, Traumatic; 108 are open to participants now.

This study's enrollment of 46 is below the median of 60 across 908 interventional studies indexed under Stress Disorders, Traumatic.

Browse Stress Disorders, Traumatic studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 686 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Woman over 18
  • Refugee or asylum seeker (habing applied to OFFPRA or with a residence permit)
  • Belonging to the SINDIANE community project
  • Having been exposed to at least one traumatic event (according to the DSM 5 definition validated by a doctor)
  • Having a PCL5 score greater than 23
  • Agreeing to participate in the study with an informed consent signed by the subject after explanations given by the investigating psychiatrist
  • Patient affiliated to a social security health care
  • Patient able to read and write arabic or french

Exclusion criteria

Exclusion Criteria:

  • Be under the age of 18
  • Be included in another intervention research
  • Presence of severe mental retardation or dementia according to DSM5
  • Persons benefiting from special protection : under article L3212-1 and L3213-1 of the Public Health Code
  • Persons referred to in articles L1121-5 to L1121-8 of the CSP
  • Existence of a high suicide risk assessed by the R.U.D.
  • Patient subject to a compulsory care measure (Law n°2011-803 of july 5, 2011 relating to the rights and protection of persons subject to psychiatric care and the terms of care)
  • Patient refusing to sign the consent or unable to receive the information necessary to give informed consent
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Experimental group

    Beneficiaries of NET therapy + standard Sindiane program management.

    Behavioral: Psychotherapy using Narrative Exposure Therapy (NET)

  • No intervention
    Control group

    Beneficiaries of the standard care of the Sindiane program.

Interventions

  • BehavioralPsychotherapy using Narrative Exposure Therapy (NET)

    There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her "Life Line" and start his/her life story with the peer mediator. The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish. The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient. To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it.

06

What researchers measure

Primary outcomes

  1. PTSD symptoms measure by PCL5

    The PCL-5 is a self reported score. The higher the score, the greater intensity of the symptoms of PTSD. It is validated in english and french with goof psychometric characteristic. The total score of the questionnaire is 80. The scale varies per question from 0 to 4: 0 = Not at all 1. = A little bit 2. = Moderately 3. = Quite a bit 4. = Extremely If the patient gets a 0, it means that he/she does not have this symptom of post-traumatic stress. On the contrary, the more the score increases and tends towards 4, the more the symptom will be present in the patient.

    Time frame: 1 month post NET therapy

Secondary outcomes

  1. Evolution of PCL5 score

    Comparaison of the PCL-5 score after therapy and at 3 and 6 moth. This endpoint is intersted in highlighting a possible improvement in symptoms at a distance from the therapy. The total score of the questionnaire is 80. The scale varies per question from 0 to 4: 0 = Not at all 1. = A little bit 2. = Moderately 3. = Quite a bit 4. = Extremely If the patient gets a 0, it means that he/she does not have this symptom of post-traumatic stress. On the contrary, the more the score increases and tends towards 4, the more the symptom will be present in the patient.

    Time frame: 3 months and 6 months

  2. Psychiatric comorbidity intensity score RHS15

    Since post traumatic stress disorder is often accompanied by comorbid disorders such as depression or addictive behavior disorder. This evaluation will allow us to assess the possible effectiveness of NET on the associated disorder. This judgment criterion will be assessed using RHS15 wich is a self administrated questionnaire validated in the creening of the main psychiatric disorders. The total of the base varies between 0 and 56. By question the scale varies between 0 and 4: 0 = Not at all 1. = A little bit 2. = Moderately 3. = Quite a bit 4. = Extremely A score of 0 means that the patient does not have a psychiatric disorder. The higher the score, the more the patient will have more and more mental disorders.

    Time frame: before the intervention, 1 month post therapy, 3 months and 6 months

  3. EvExperience indicators intensity score (GSE)

    This main judgment criterion is concerned with the overall functioning of person concerned. Indeed, it makes it possible to evaluate the satisfaction and the power to act of the person. It is used to have a broader assesment of the expected benefits of PTSD treatment. The total score varies between 10 and 40. The more the patient scores, the higher his or her sense of self-efficacy.

    Time frame: before the intervention, 1 month post therapy, 3 months and 6 months

07

Study locations

1 site
  • Assistance Publique Hôpitaux Marseille
    Marseille, Bouches-du-Rhône 13354, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05407337
Lead sponsor
Assistance Publique Hopitaux De Marseille
Responsible party
Sponsor
First posted
Jun 7, 2022
Start date
Nov 22, 2022
Primary completion
Oct 23, 2023
Completion
Apr 23, 2024
Last update
Aug 9, 2024

Study contacts

François CREMIEUX
study director · Assistance Publique Hôpitaux Marseille
Clotilde IZABELLE, Dr
principal investigator · Assistance Publique Hôpitaux Marseille

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion